Side effects may vary based on why you are using bevacizumab. Tell your health care provider if you have any of these side effects that bother you. Bleeding (see below) Headache Increased blood pressure (see below) Runny nose Kidney damage (see below) Change in how things taste Skin ...
Learn about the possible side effects of mCRC treatment with Avastin® (bevacizumab). See full safety for more information.
Side effects Dosage information During pregnancy FDA approval history Drug class: VEGF/VEGFR inhibitors Breastfeeding En español Patient resources Other brands Zirabev, Mvasi, Avzivi, Vegzelma, Alymsys Professional resources Avastin prescribing information Bevacizumab (AHFS Monograph) Other brands Zirabev,...
Managing side effects (general information)For healthcare professionals Applies to bevacizumab: intravenous solution. Gastrointestinal adverse events Very common (10% or more): Abdominal pain (up to 61%), vomiting (up to 52%), anorexia (up to 43%), constipation (up to 40%), diarrhea (up ...
Find information about how long Avastin® (bevacizumab) treatment should be taken for the treatment of advanced stage III/IV or recurrent platinum-treated ovarian cancer. See full safety for more information.
Side Effects of Bevacizumab Bevacizumab may cause dizziness, dry mouth, fatigue, heartburn and loss of appetite. In rare cases, it may cause severe side effects such as blood clots in the lungs, hemorrhaging, holes in the stomach and low white blood cell count. These potentially deadly complic...
Find out more about MVASI® (bevacizumab-awwb) an Avastin® (bevacizumab) Biosimilar. See Important Safety & Prescribing Info.
Bevacizumab (Avastin®) is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-lin
In February, the US Food and Drug Administration (FDA) approved Avastin (bevacizumab) for the treatment of advanced colorectal cancer. Avastin is an angiogenesis inhibitor. It works by targeting and inhibiting the functioning of vascular endothelial growth factor (VEGF), which stimulates new blood ...
When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking the beginning for a new line of anti-cancer treatments, bevacizumab remains the...